Rhabdomyolysis Following Initiation of Posaconazole Use for Antifungal Prophylaxis in a Patient With Relapsed Acute Myeloid Leukemia: A Case Report. (February 2017)

• Record Type: Journal Article
• Authors: Mody, Mayur D.; Ravindranathan, Deepak; Gill, Harpaul S.; Kota, Vamsi K.
• Is Part Of: Journal of investigative medicine high impact case reports. Volume 5:Number 1(2017)
• Publication Date: 2017-02
• Subjects: posaconazole -- rhabdomyolysis -- AML -- acute myeloid leukemia; Internal medicine -- Periodicals; Medical care -- Periodicals; 616.005
• DOI: 10.1177/2324709617690747
• Languages: English
• ISSNs: 2324-7096

Abstract

Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications, posaconazole is known to have many side effects and drug-drug interactions. We present a patient who developed rhabdomyolysis after being started on posaconazole for prophylaxis in the setting of relapsed acute myeloid leukemia.